Company Overview and News

 
Critical Control Announces Second Quarter 2018 Financial Results

2018-08-16 globenewswire
CALGARY, Alberta, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (TSX: CCZ.PR.A) today reported its financial results for the three and six months ended June 30, 2018.
CCZ CCZFF

 
Critical Control Announces Second Quarter 2018 Financial Results

2018-08-15 globenewswire
CALGARY, Alberta, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (TSX: CCZ) today reported its financial results for the three and six months ended June 30, 2018.
CCZ CCZFF

 
Critical Control Announces Its Annual General Meeting Voting Results

2018-06-19 globenewswire
CALGARY, Alberta, June 19, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (“Critical Control” or the “Corporation”) (TSX:CCZ) announces that all the motions put forth at its annual general meeting held in Calgary on June 19, 2018 were approved by the shareholders. The detailed results of the voting are as follows:
CCZ CCZFF

 
Critical Control Declares Dividend

2018-06-11 globenewswire
CALGARY, Alberta, June 11, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (“Critical Control” or the “Corporation”) (TSX:CCZ) (TSX:CCZ.PR.A) announces that the directors of the Corporation declared a quarterly cash dividend on its series A preferred shares of $0.04 per share, payable on or about June 30, 2018 to shareholders of record at the close of business on June 15, 2018. This dividend represents a cash dividend of $0.
CCZ CCZFF

 
Early Warning Report

2018-06-06 globenewswire
CALGARY, Alberta, June 06, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (TSX:CCZ) ("Critical Control") announces that Mr. Alykhan Mamdani, President and CEO of Critical Control has purchased 2,827,504 common shares of Critical Control at a purchase price of $0.19 per share in a private transaction.
CCZ CCZFF

 
Critical Control Announces First Quarter 2018 Financial Results

2018-05-09 globenewswire
CALGARY, Alberta, May 08, 2018 (GLOBE NEWSWIRE) -- Critical Control Energy Services Corp. (TSX:CCZ) today reported its financial results for the three months ended March 31, 2018.
CCZ CCZFF

 
Critical Control Energy Services Corp. - Early Warning Report

2018-04-13 globenewswire
CALGARY, Alberta, April 13, 2018 (GLOBE NEWSWIRE) -- Alykhan Mamdani, President and CEO of Critical Control Energy Services Corp. (“Critical Control”) (TSX:CCZ), has filed an Early Warning Report in accordance with National Instrument 62-103 The Early Warning System and Related Take Over Bids and Insider Reporting Issues, in connection with his acquisition of 33,761 common shares of Critical Control under Critical Control’s employee share purchase plan (the “ESPP Acquisition”).
CCZ CCZFF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to TSX:CCZ / Criticalcontrol Solution on message board site Silicon Investor.

CCZ - COMMERCIAL CONSOLIDATORS - Company Website http://comm CCZ - COMMERCIAL CONSOLIDATORS - Company Website http://comm CCZ - COMMERCIAL CONSOLIDATORS - Company Website http://comm CASTELLO CASINO CORP. (CCCZ/CSTC) CASTELLO CASINO CORP. (CCCZ/CSTC) CASTELLO CASINO CORP. (CCCZ/CSTC)